Immunogenicity of hepatitis a vaccine in children with cancer
PEDIATRIC HEMATOLOGY AND ONCOLOGY, vol.23, no.8, pp.619-624, 2006 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 23 Issue: 8
- Publication Date: 2006
- Doi Number: 10.1080/08880010600907239
- Journal Name: PEDIATRIC HEMATOLOGY AND ONCOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.619-624
- Hacettepe University Affiliated: Yes
Abstract
This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. Twenty-eight patients with lymphomas or solid tumors and who had negative serology for hepatitis A were enrolled. The median age was 4.7 years (range 2-16). The patients received 1440 IU hepatitis A vaccine at 0 and 6 months. Seroconversion rates at the first and seventh months were 60% (n = 17/28 patients) and 89% (n = 24/27 patients). No adverse effects were observed. The hepatitis A vaccine was found to be effective and safe in children with cancer.